目的 探讨降糖通脉联合格列喹酮治疗2型糖尿病的有效性和安全性。方法 选取澄迈县人民医院2016年3月-2018年3月收治的2型糖尿病患者200例，随机分成对照组和治疗组，每组各100例。对照组口服格列喹酮片，1片/次，2次/d；治疗组患者在对照组基础上口服降糖通脉胶囊，3粒/次，3次/d。两组患者均连续治疗2个月。观察两组患者临床疗效，同时比较治疗前后两组患者空腹血糖、空腹C肽、糖化血红蛋白、症状积分、DSQL评分及HOMA-IS、HOMA-IR和肿瘤坏死因子-α（TNF-α）水平。结果 治疗后，对照组临床有效率为88.00%，显著低于治疗组的97.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者空腹血糖、糖化血红蛋白水平均显著降低（P<0.05），空腹C肽水平均显著升高（P<0.05），且治疗组患者空腹血糖、空腹C肽及糖化血红蛋白水平明显好于对照组（P<0.05）。治疗后，两组患者症状积分显著降低（P<0.05），DSQL评分显著升高（P<0.05），且治疗组患者症状积分和DSQL评分明显好于对照组（P<0.05）。治疗后，两组患者HOMA-IR、TNF-α水平均显著降低（P<0.05），HOMA-IS水平均显著升高（P<0.05），且治疗组患者HOMA-IS、HOMA-IR和TNF-α水平明显优于对照组（P<0.05）。结论 降糖通脉联合格列喹酮治疗2型糖尿病疗效确切、安全性高，同时还能够改善患者的生活质量和临床症状。

Objective To investigate the efficacy and safety of Jiangtang Tongmai Capsules combined with gliclaquinone in treatment of type 2 diabetes. Methods Patients (200 cases) with type 2 diabetes in Chengmai County People's Hospital from March 2016 to March 2018 were randomly divided into control and treatment groups, and each group had 100 cases. Patients in the control group were po administered with Gliquidone Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Jiangtang Tongmai Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the fasting blood glucose, fasting C-peptide, glycosylated hemoglobin, symptom scores, DSQL scores, HOMA-IS, HOMA-IR, and TNF-α levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 88.00%, which was significantly lower than 97.00% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the fasting blood glucose and glycosylated hemoglobin in two groups were significantly decreased (P<0.05), but fasting C-peptide levels were significantly increased (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the symptom scores in two groups were significantly decreased (P<0.05), but DSQL scores were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the HOMA-IR and TNF-α levels in two groups were significantly decreased (P<0.05), but HOMA-IS levels were significantly increased (P<0.05), and the HOMA-IS, HOMA-IR and TNF-α levels in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Jiangtang Tongmai Capsules combined with gliclaquinone is effective and safe in treatment of type 2 diabetes, can also improve the quality of life and clinical symptoms of patients.

R977